Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)

Background and Purpose— In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk stratification schemes have been devised to identify patients for whom the absolute benefits of OAC exceed its risks. Methods— Participants were risk-stratified with the widely-used CHADS2 scheme. Treatment-specific rates of stroke and major bleeding were calculated for patients with a CHADS2=1 and compared to those with a CHADS2>1. Results— Observed stroke rates for those with a CHADS2=1 were 1.25% per year on C+A and 0.43% per year on OAC (RR=2.96, 95% CI: 1.26 to 6.98, P=0.01). Among patients with a CHADS2>1, the stroke rates were 3.15% per year on C+A and 2.01% per year on OAC (RR=1.58, 95% CI: 1.11 to 2.24, P=0.01) (P for interaction between stroke risk category and efficacy of OAC=0.19). The risk of major bleeding during OAC was significantly lower among patients with CHADS2=1 (1.36% per year) compared with CHADS2>1 (2.75% per year) (RR=0.49, 95% CI 0.30 to 0.79, P=0.003). Conclusions— In this clinical trial, patients with a CHADS2=1 had a low risk of stroke, yet still derived a modest (<1% per year) but statistically significant absolute reduction in stroke with OAC and had low rates of major hemorrhage on OAC.

[1]  A. Shields,et al.  Trends in private insurance, Medicaid/State Children's Health Insurance Program, and the health-care safety net: implications for asthma disparities. , 2007, Chest.

[2]  G. Lip.  Coronary artery disease and ischemic stroke in atrial fibrillation. , 2007, Chest.

[3]  G. Lip,et al.  Effect of hypertension on anticoagulated patients with atrial fibrillation. , 2007, European heart journal.

[4]  J. Le Heuzey,et al.  Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. , 2006, American heart journal.

[5]  M. Woodward,et al.  Perindopril-Based Blood Pressure–Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack , 2005, Stroke.

[6]  Palle Petersen,et al.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.

[7]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[8]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[9]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[10]  J. Healey,et al.  Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. , 2003, The American journal of cardiology.

[11]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[12]  Carl van Walraven,et al.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. , 2002, JAMA.

[13]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[14]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[15]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[16]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[17]  G. Lip.  Thromboprophylaxis for atrial fibrillation , 1999, The Lancet.

[18]  G. Albers.  Choice of antithrombotic therapy for stroke prevention in atrial fibrillation: warfarin, aspirin, or both? , 1998, Archives of internal medicine.

[19]  B. Gage,et al.  Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. , 1998, Stroke.

[20]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[21]  Frank J. Hildner,et al.  ArticlesAntithrombotic Therapy in Atrial Fibrillation , 1989 .

[22]  A. Waldo.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialConnolly SJ, for The ACTIVE Writing Group for the ACTIVE Investigators (Hamilton Health , 2007 .

[23]  M. Glanz,et al.  The Sharer , 2000, Annals of Internal Medicine.

[24]  L. Pearce.  Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. , 1995, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[25]  H. Tohgi,et al.  The risk of cerebral infarction in non-valvular atrial fibrillation: effects of age, hypertension and antihypertensive treatment. , 1991, European Neurology.